Distribution of Hepatitis C Virus Genotypes Among Patients With Hepatitis C Virus Infection in Hormozgan, Iran

Seyedeh Farzaneh Mousavi 1, Seyed Hamid Moosavy 1,*, Seyed Moayed Alavian 2,3, Hajar Eghbali 1, Hamidreza Mahboobi 4,5

1Shahid Mohammadi Hospital of Hormozgan, University of Medical Sciences, Bandar Abbas, IR Iran
2Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3Middle East Liver Diseases Center (MELD Center), Tehran, IR Iran
4Infectious and Tropical Diseases Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, IR Iran
5Department of Psychology, Payame Noor University, Tehran, IR Iran

*Corresponding Author: Seyed Hamid Moosavy, Shahid Mohammadi Hospital of Hormozgan, University of Medical Sciences, Bandar Abbas, IR Iran. Tel: +98-9177635854, Fax: +98-7613354056, E-mail: seyedhamidmoosavy@gmail.com.

Received: August 23, 2013; Revised: September 29, 2013; Accepted: November 23, 2013

Background: More than 170 million people in the world are infected with Hepatitis C Virus (HCV). Determination of HCV genotype before starting the treatment is required, because HCV genotype affects the course of treatment and drug dosage

Objectives: We aimed to evaluate HCV genotypes among patients with positive results for anti-HCV in Bandar Abbas from 2011 to 2012.

Patients and Methods: Five hundred and nine consecutive patients with established chronic HCV infection referred to Behavioral Diseases Consultation Center, Blood Transfusion and Center for Special Diseases from March 2011 to March 2012 were enrolled in this cross sectional study. Five mL of peripheral blood was taken from precipitants and viral RNA extracted after plasma separation. Hepatitis C Virus RNA was detected by reverse transcriptase-nested polymerase chain reaction (RT-nested PCR) assay and then HCV genotypes analyzed using restriction fragment length polymorphism (RFLP) method.

Results: In overall, 509 patients enrolled to this study. The mean age of these patients was 38.87±9.55 years ranging from 1 to 90 years. Routes of transmission were: 238 (46.7%) inject of substance, 149 (29.3%) unknown rout, 62 (12.2%) blood transfusion, 50 (9.8%) sexual contact, and 10 (2%) mother to child. Frequency of HCV genotypes were: 316 (62.1%) 1a, 117 (23%) 1b, and 76 (14.9%) 3a. there was no significant association between HCV genotypes and gender, educational degree, risk factor of Hepatitis C, job, monthly income, HIV infection, Hepatitis B virus (HBV) infection, Intravenous drug injection, and underlying disease (P > 0.05).

Conclusions: This results the same as many similar studies demonstrated that common HCV genotypes in Iranian patients were ta, 3a and 1b, respectively. Patients with ta and 1b genotypes have lower responses to interferon treatment, and it is reasonable to perform early screening to diagnose and determine HCV genotype for effective treatment and diagnose high-risk cases.

Keywords: Hepatitis C; Genotype; Iran

1. Background

More than 170 million people worldwide are infected with Hepatitis C Virus (1). Hepatitis C is a blood-borne disease and the main risk factor is exposure to infected blood or blood products such as: transfusion with unscreened blood and blood products, needle-sharing among Intravenous (IV) drug abusers, and needle-stick injuries in health care workers. The most common cause of transmission is needle or syringe sharing among drug abusers with a prevalence between 31 to 89 percent according to different geographical areas. Risk of infection for some groups of patients such as, patients on hemodialysis, those with hemophilia infants of mothers with HCV infection, and multipartner individuals are dramatically higher. Prevalence of HCV among patients on hemodialysis in Iran is 5.5% to 55.9% in different cities, although this number for patients with hemophilia is 15.65 to 76.7%.

HCV comprises six major genotypes (genotypes 1 to 6) and several subtypes (a, b, c, etc.) which have different geographical distribution (2). It is needed to determine HCV genotype prior to treatment, because this is the genotype which determines treatment period and drug dosage. In addition, genotype is an important preventive agent for probability of viral tolerance, and probability of obtaining and sustained virologic response (3).

There exists a certain geographical distribution of HCV genotypes. Genotype 1 is the most common one in the US and Europe; and genotypes 2 and 3 have the lowest prevalence in these regions and genotypes 4, 5, and 6...
are rare. Genotype 3 is the most common in India, Far East and Australia. Genotype 4 is the most common in Africa, the Middle East, and it seems that the most common European type is related to IV drug abusers and homosexual males. Genotype 5 is the most common in southern Africa, and genotype 6 is the most common in Hong Kong, Vietnam and Australia (4-7). It sounds that the prevalence and incidence of different HCV genotypes in geographical regions and periods of time are due to distribution mode and evolution of risk factors (8).

Several studies were performed in Iran to explore this geographical distribution. In a study conducted by Joukar et al. (2009), in Guilan it was found that the most common genotypes among patients on hemodialysis are 1a and 3a (59.38%) (9). Data gathered from 16 provinces in a study by Haji et al. (2009), in Tehran indicated that the most prevalent genotype was 3a (46.6%) and then genotype 1a (17.47%) ranked second. The findings of this study during four years showed that HCV infection with genotypes 1b, 3a, has increased from 12.2% and 38.9% to 18.9% and 46.5% in the fourth year (10). Another study performed by Samimi-Rad et al. (2008) in Markazi province revealed that the overall prevalence of Hepatitis C was 5.4% and the prevalent subtype among patients on hemodialysis was 1a (50%), then genotypes such as 4 (25%), 3a (12.5%) and 1b (12.5%) ranked second to fourth (11). Currently this disease is treated by pegylated IFN-α and Ribavirin which has severe side effects and its outcome depends totally on the HCV genotype (12-14).

2. Objectives

Based on the fact that HCV genotype varies in different geographical regions and since the type of effective treatment and response to treatment varies in different genotypes of this virus, these authors decided to investigate the distribution of HCV genotypes of patients with positive results for HCV in Hormozgan, 2011 to take more effective treatment decisions in this field.

3. Patients and Methods

3.1. Study Population

In this cross sectional study 509 patients with positive results for anti-HCV antibody and HCV-RNA tests referred to Behavioral Diseases Consultation Center, Blood Transfusion and Center for Special Diseases were enrolled between March 2011 and March 2012. The present study was approved by committee of medical student thesis of Hormozgan University of Medical Sciences (HUMS). Patients were informed about the study and then an informed consent was obtained from each participant. Inclusion criteria were positive results for plasma genomic HCV-RNA and anti-HCV antibodies. For all patients a two-part check list was prepared as follows:

1. Questions regarding demographic information, 2. Questions about route of infection, time of diagnosis, presence of Blood born coinfections, underlying disease, addiction to drugs or previous abuse.

3.2. Sample Collection and RNA Extraction

About 5 milliliter of peripheral blood was taken from each participant into EDTA-containing vacutainer tubes. Plasma was obtained from whole blood by centrifugation and storage at -80 °C for later detection. Viral RNA was extracted from plasma sample using High Pure Viral Nucleic Acid Kit (Roche Diagnostics GmbH, Mannheim, Germany), according to the manufacturer’s instructions.

3.3. cDNA Synthesis and Hepatitis C Virus Genotyping Using Restriction Fragment Length Polymorphism Assay

The Genomic HCV-RNA in plasma sample was detected using reverse transcriptase-nested polymerase chain reaction (RT-nested PCR) method. cDNA synthesis from viral RNA and two round nested-PCR were performed as previously described elsewhere (15). Hepatitis C virus-genotypes were analyzed in RT-nested PCR products using restriction fragment length polymorphism (RFLP) assay. The nested-PCR and RFLP assay were performed using primers from the 5' -untranslated region (5'-UTR) as described previously by Pohjanpelto et al. in details (16). The second round of PCR products (173-bp) with digested PCR products by special restriction enzymes and appropriate controls with 50bp molecular weight size marker (Fermentas GmbH, St. Leon-Rot, Germany) were visualized using 3% agarose gel electrophoresis. Different HCV Genotypes were determined based on the molecular weight of each fragment of PCR product. The results of HCV genotyping by RFLP assay were confirmed by sequencing of 5'-UTR of HCV. The 5'-UTR was amplified from viral RNA extracted from plasma specimens of 10 randomly selected participants with Pfu DNA polymerase and the PCR products were sequenced using dye termination method by ABI 3730 XL sequencer.

3.4 Statistical Analysis

Data was analyzed by descriptive statistical methods (frequency, Standard Deviation, Mean) and statistical test Chi-square using SPSS version 13.

4. Results

Totally 509 subjects took part in the present study. The average age was 38.87 ± 9.55 years ranging from 1 to 90 years. Disease transmission methods in this study were IV drug abuse (%56.7, N = 238), unknown (29.3%, N = 149), transfusion (12.2%, N = 62), sexual contact with infected individuals (9.8%, N = 50), and mother to child (2%, N =
which this vertical transmission is more than previous results from other parts of Iran. Prevalence of HCV genotypes in these subjects was as follows: 316 (62.1%) 1a, 117 (23%) 1b, and 76 (14.9%) 3a. Distribution of genotypes of hepatitis C with sex, HIV infection, hepatitis B (HBV) infection and underlying diseases has been illustrated in Table 1.

| HCV-Genotype | Presentation Patients | P value |
|--------------|-----------------------|---------|
| 3a (N = 76)  | 1b (N = 117)          | 1a (N = 316) |
| Male/Female, (%) | 70/6 (92.1)          | 112/5 (95.7) | 296/20 (93.7) | Non-significant |

Transmission of HCV

|                      | Post-transfusion | IV drug abuse | Sexual | unknown | Prenatal |
|----------------------|------------------|---------------|--------|---------|----------|
| 3a (N = 76)          | 14 (18.4)        | 34 (44.7)     | 7 (9.2)| 19 (25) | 2 (2.6)  |
| 1b (N = 117)         | 14 (12)          | 55 (47)       | 15 (12.8)| 32 (27.4)| 1 (0.9)  |
| 1a (N = 316)         | 34 (10.8)        | 149 (47.2)    | 28 (8.9)| 98 (31) | 7 (2.2)  |

Underlying Disease

|                  | Renal failure | HBV Coinfection | HIV Coinfection |
|------------------|--------------|-----------------|-----------------|
| 3a (N = 76)      | 0 (0.0)      | 1 (1.3)         | 13 (17.1)       |
| 1b (N = 117)     | 0 (0.0)      | 3 (2.6)         | 55 (21.4)       |
| 1a (N = 316)     | 1 (0.3)      | 21 (6.6)        | 65 (20.6)       |

Complications

|                  | Cirrhosis  |
|------------------|------------|
| 3a (N = 76)      | 0 (0.0)    |
| 1b (N = 117)     | 0 (0.0)    |
| 1a (N = 316)     | 1 (0.3)    |

Also distribution of a variety of Hepatitis C genotypes with level of education, job has been shown in Table 2. Our findings indicated that there was not any significant association between various hepatitis C genotypes and gender, level of education, risk factors for hepatitis C, job, HIV infection (103 patients), HBV infection (25 patients), and the presence of underlying diseases (P > 0.05).

| Presentation Patients | HCV-genotype, No. (%) | P value |
|-----------------------|------------------------|---------|
| 1a (N = 316)          | 1b (N = 117)           | 3a (N = 76) |
| Occupation            | Non-Significant        | Non-Significant |
| Unemployed            | 108 (34.2)             | 41 (35) | 25 (32.9) |
| Employee              | 108 (34.2)             | 39 (33.3)| 28 (36.8) |
| Free job              | 44 (13.9)              | 21 (17.9)| 11 (14.5) |
| Housekeeper           | 5 (1.6)                | 3 (2.6)  | 2 (2.6)  |
| Student               | 9 (2.8)                | 3 (2.6)  | 1 (1.3)  |
| Scholar               | 7 (2.2)                | 3 (2.6)  | 3 (3.9)  |
| Laborer               | 34 (10.8)              | 6 (5.1)  | 3 (3.9)  |
| Retired               | 1 (0.3)                | 1 (0.9)  | 3 (3.9)  |
| Education             | Non-Significant        | Non-Significant |
| Illiterate            | 92 (29.1)              | 34 (29.1)| 16 (21.1) |
| Lower than diploma    | 61 (19.3)              | 25 (21.4)| 16 (21.1) |
| Diploma               | 92 (29.1)              | 36 (30.8)| 25 (32.9) |
| Licentiate            | 70 (22.2)              | 22 (18.8)| 19 (25)  |
| Higher than licentiate| 1 (0.3)                | 0 (0.0)  | 0 (0.0)  |
5. Discussion

The most frequent genotypes in our study were 1a (62.1%), 1b (23%), and 3a (14.9%) respectively. Some studies in Iran have reported different results. Genotype 3a (61.2%) was reported as the most frequent genotype in Isfahan province followed by 1a (29.5%) and 1b (5.1%) genotypes (17). Alavian et al. reported the distribution of HCV genotypes as follows; genotype 1 in 57%, genotype 3 in 35%, and genotype 2 in 1%, and mixed genotype in 4% of Iranian patients with thalassemia (18).

The information about the prevalence of different HCV genotypes in Iran is variable according to the study population and geographical setting. We have summarized the results of some studies in Table 3. As shown in Table 3 the most frequent HCV genotypes in Iran were 1a and 3a. As shown in this table the frequency of HCV genotypes is variable based on study population and geographical areas. Some studies have focused on patients on hemodialysis and those with hemophilia, while others investigated patients with HCV referred to clinics.

Table 3. HCV Genotypes Frequency in Iran

| Study                           | Population                             | Province            | No. of Patients Studied | Results                                      |
|---------------------------------|----------------------------------------|---------------------|-------------------------|----------------------------------------------|
| Assarehzadegan et al. (2009)    | Patients on hemodialysis               | Khuzestan province  | 34                      | 1a (41.1%), 3a (35.2%), 1b (23.5%)           |
| Samimi Rad et al. (2007)        | Patients with thalassemia and those with hemophilia | Markazi province    | 2 patients with thalassemia and 23 with hemophilia | Hemophilia: Genotype one in 50%, three in 18.2%, two in 4.54%, and mixed in 27.3%, Thalassemia: two (40%) had positive results for HCV RNA and one sample was subtype 3a. |
| Keyvani et al. (2007)           | Patients with hepatitis C referred to hepatitis clinics | Tehran province    | 2231                    | 1a (39.7%), 3a (27.5%), and 1b (12.1%)       |
| Kabir et al. (2006)             | Patients with HCV                      | Tehran              | 156                     | 1a (37.8), 3a (28.9%), 1b (16.7%).           |
| Hosseini-Moghaddam et al. (2006)| Patients on hemodialysis               | Tehran              | 66                      | 3a (30.3), 1a (28.8%), 1b (18.2%), 4 (16.7%) |

Also the results of studies in our neighborhood countries are different. One study in Turkey have reported genotype 1b in 84.7% of patients with HCV followed by 3a (4.2%) and 1 (3.8%), which is not compatible with our results (24). In Pakistan the most frequent genotypes were 3a (40.96%), 3b (15.66%), and 1a (9.63%) respectively (25). In Saudi Arabia genotype 4 (50%) was the most common genotype followed by genotype 1b (40.9%), and 1a (9.1%) (26, 27). In China, one study on patients with HCV and HIV coinfection reported genotype 6a (39.3%) as the most frequent genotype followed by genotypes 1b (24.7%), 3b (18%), and 3a (9.8%) (28).

The present findings showed that there was no significant association between a variety of hepatitis C genotypes and gender, level of education, and risk factors for hepatitis C, job, income, HIV infection, HBV infection, IV drug abuse and presence of underlying diseases. In addition, the present findings indicated that there was no significant association between the types of HCV genotype and the underlying diseases. The results of the study by Amini et al. and Kabir et al. are in agreement with the present findings. They found no significant difference between the HCV genotypes and risk factors and demographic characteristics (22, 29). Keyvani et al. indicated an increase in frequency of genotype 1b with increasing age (21).

We did not find any significant association between HCV genotype and underlying diseases or complications of the disease. It is shown that patients with genotypes 1a and 1b tended to have more severe liver disease and lower response to interferon therapy (30). Also patients with genotype 1b are at higher risks for hepatocellular carcinoma (31). Alavian’s study on patients with thalassemia and simultaneously HCV infection, showed that dominant genotype 1 may result in splenectomy and increased ferritin in blood (18).

The importance of determination of the most frequent genotypes in each area is the differences in treatment response and prognosis of patients (32-36).

The study showed that the most frequent genotypes of hepatitis C in Bandar Abbas are 1a, 1b, and 3a respectively. This frequency is different in other provinces in Iran and the neighboring countries. Therefore, we recommend more studies on the treatment options available for patients in each area based on the most frequent genotypes.

Acknowledgements

This study is the result of internal medicine residency thesis which was approved by the research committee of Hormozgan University of Medical Sciences (HUMS). The article is prepared based on the scientific writing guidelines.

Authors’ Contribution

Dr. Alavian Critical revision of the manuscript for im-
References

1. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5(6):453-63.
2. Joukar F, Khalesi AK, Jalashad R, Rahimabadi MS, Mansour-Ghanaei F. Distribution of hepatitis C virus genotypes in haemo-
dialysis patients of Guilan, northern Islamic Republic of Iran. East Mediterr Health J. 2012;18(3):236-40.
3. Bulh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C Virus: quasispecies and genotypes. Semin Liver Dis. 1995;15(1):41-63.
4. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechtot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 1994;19(5):3321-4.
5. Simmonds P, Bulh J, Combet C, Delege G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42(4):962-73.
6. Lau JY, Davis GL, Prescott LE, Maertens G, Qian K, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med. 1996;124(10):868-76.
7. Dusheiko G, Schniovitz-Weiss H, Brown D, Mcomin F, Yap PL, Shercock S, et al. Hepatitis C Virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatol-
tology. 1994;19(1):113-8.
8. Walesy A, Alter MJ. Epidemiology of hepatitis C: geographic differ-
tences and temporal trends. Semin Liver Dis. 2000;20(1):34-46.
9. Khalesi AA, Besharati S. Distribution of HCV genotypes in hemo-
dialysis patients of Guilan. 2010;28(3):277-84.
10. Haja M, Amirzargar A, Khedmat H, Shahrokhi N, Farzanehkhah M, Ghorishi S, et al. Genotyping Pattern among Iranian HCV Posi-
tive Patients. Iran J Public Health. 2010;39(2):39-44.
11. Samimi-Rad K, Hosseini M. Hepatitis C virus infection and hcv genotypes of hemodialysis patients. Iranian J Pub Health. 2008;37(3).
12. Jolpling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005;309(5740):1577-81.
13. Jolpling CL, Schutz S, Sarnow P. Position-dependent function for a tandem microRNA miR122-binding site located in the hepatitis C Virus RNA genome. Cell Host Microbe. 2008;4(3):277-85.
14. Randall G, Paris M, Cooper JP, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, et al. Cellular cofactors affecting hepatitis C virus infec-
tion and replication. Proc Natl Acad Sci U S A. 2007;104(31):12288-94.
15. Bokharaei-Salimi F, Keyhani H, Monavari SH, Alavian SM, Madjz Z, Toosi MN, et al. Occult hepatitis C virus infection in Iranian pa-
tients with cryptogenic liver disease. J Med Virol. 2011;83(6):989-95.
16. Pohjanpeltto P, Lappalainen M, Widel A, Asikainen K, Paunio M. Hepatitis C genotypes in Finland determined by RFLP. Clin Diagn Virol. 1996;17(16).
17. Zarkesh-Esfahani SH, Kardi MT, Edalati M. Hepatitis C virus geno-
type frequency in Isfahan province of Iran: a descriptive cross-
sectional study. Virol J. 2007;4:99.
18. Alavian SM, Mirti SM, Khesvari M, Elizee PK, Behnava B, Tab-
tabai SV, et al. Distribution of hepatitis C virus genotype in Iran-
ian multiply transfused patients with thalassemia. Transfusion. 2009;49(10):2195-9.
19. Assarehzadegan MA, Shakerinejad G, Noroozkhohnejad R, Amini A, Rahim Rezaee SA. Prevalence of hepatitis C and B infection and HCV genotypes among hemodialysis patients in Khorasan prov-
ince, southwest Iran. Saudi J Kidney Dis Transplant. 2009;20(4):681-4.
20. Samimi-Rad K, Shahbazi B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia. 2007;13(2):256-61.
21. Keyhani H, Alizadeh AH, Alavian SM, Ranjbar M, Hamedi S. Distrib-
ution frequency of hepatitis C virus genotypes in 2231 patients in Iran. Hepatol Res. 2007;37(2):201-5.
22. Kabir A, Alavian SM, Keyhani H. Distribution of hepatitis C Virus genotypes in patients infected by different sources and its cor-
relation with clinical and virological parameters: a preliminary study. Comp Hepatol. 2006;5(4).
23. Hosseini-Moghaddam SM, Keyhani H, Kazemiyen SM, Basiri A, Aghel N, et al. Distribution of hepatitis C Virus genotypes among hemodialysis patients in Tehran-a multicenter study. J Med Virol. 2006;78(5):569-71.
24. Tyczak S, Ulger M, Aslan G, Yaras S, Altintas E, Szezin O, et al. De-
termination of hepatitis C virus genotype distribution in Mersin province, Turkey. J Microbiol Vol. 2013;47(2):332-8.
25. Idrises M, Rafique S, Rehman I, Akbar H, Yusaf MZ, Butt S, et al. Hepatitis C virus genotype 3a infection and hepatocel-
cular carcinoma: Pakistan experience. World J Gastroenterol. 2009;15(40):5080-5.
26. Al-Knawy B, Okamoto H, Ahmed El-Mekki A, Elbargi Khalfalla M, Al Wabel A, Qazi F, et al. Distribution of hepatitis C genotype and co-
infection rate with hepatitis G in Saudi Arabia. Hepatol Res. 2002;24(2):95.
27. Borsikin YS, Bakir TM, al-Ashk AI, Booth JC. Is hepatitis C vi-
rus genotype 4 predominant in Saudi Arabia? New Microbiol. 1999;22(3):373-80.
28. Zhao R, Peng J, Tang I, Huang H, Liu M, Kong W, et al. Epidemi-
ological distribution and genotype characterization of hepatitis C virus and HIV co-infection in Wuhan, China, where the preva-
ience of HIV is low. Med Virol. 2011;85(5):2712-23.
29. Amini S, Mahmoodi Farahani M, Joulaie M, Ahmadipour MH. Distribution of hepatitis C virus genotypes in Iran: a population-
based study. Hepat Mon. 2009;2009(2, Spring):95-102.
30. Zin NN, Rakela J, Krawitt EL, Reddy KR, Tomina H, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med. 1996;125(5):364-9.
31. Lopez-Labrador FX, Ampurdanes S, Forns X, Castells A, Saiz JC, Costa J, et al. Hepatitis C virus (HCV) genotypes in Span-
ish patients with HCV infection: relationship between HCV genotype ib, cirrhosis and hepatocellular carcinoma. J Hepatol. 1999;37(4):599-65.
32. McNaughton AL, Thomson EC, Templeton K, Gunson RN, Leitch EC. Mixed genotype hepatitis C infections and implications for treatment. Hepatology. 2013.
33. Pavan MH, Pavin EJ, Fonseca Jr FL, Zantut-Wittmann DE. Virus C genotype predisposes to primary hypothyroidism during interferon-alpha treatment for chronic hepatitis C. Braz J Infect Dis. 2011;15(5):449-56.
34. O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, et al. An IL28B genotype-based clinical prediction model for treat-
ment of chronic hepatitis C. PLoS One. 2011;6(7).
35. Nguyen CM, Mendes M, Tsunoda S, Ma JD. Interleukin-28B gene-
type testing to determine response to the combination of pe-
gylated-interferon and ribavirin for the treatment of hepatitis C virus. PLoS Curr. 2013;R001N207.
36. Moghadam A, Alavi E, Reinton N, King-Larsen H, Verbaan H, Bjørk J, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 1 infection. Hepatology. 2011;53(3):746-54.